Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $118.25 indicates a 28.6% upside potential.The average comprises four short-term price targets ranging from a low of $78 to a high of $150, with a standard deviation of $30.42. While the lowest estimate indicates a decline of 15.2% from the current pr ...

Shares of Corcept Therapeutics Incorporated (CORT) were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. The ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR). Per management, data from the ROSELLA study suggested that ...

This drug developer is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of -32%. Revenues are expected to be $177.97 million, up 21.2% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. Corcept Therapeutics (CORT) shares ral ...

Corcept Therapeutics (NASDAQ: CORT ) recently shared that its Phase 3 ROSELLA trial met its primary goal, and the stock is up over 80% in trading on March 31, 2025. In our view, the results are very promising and may Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CORT over the next 72 hours. I wrote this art ...

At an interim evaluation of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel had a significant improvement in OS, with a median OS of 16.0 months, compared to 11.5 months for patients receiving nab-paclitaxel alone. Corcept Therapeutics Incorporated CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded ind ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

It has been about a month since the last earnings report for Corcept Therapeutics (CORT) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since The ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to w ...

Shares of Corcept Therapeutics Incorporated (CORT) have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing strong demand in recent quarters and the trend is likely to continue in 2025.The company’s top line solely comprises product sales from Korlym. Sales of the drug increased almost 40% ye ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated regarding potential securities fraud or unlawful business practices [1] - A lawsuit has been filed against Corcept by a group of health insurers, alleging manipulation of the patent process to hinder Teva Pharmaceutical's generic product launch of Korlym [2] - Following the news of the lawsuit, Corcept's stock price experienced a significant decline of $8.44 per share, or 11.48%, closing at $65.09 per share [3] Company Overview - Corcept Therapeutics is known for its product Korlym, which has been a best-seller in its category [2] - The company is facing legal challenges that may impact its market position and stock performance [2][3] Legal Context - The lawsuit against Corcept highlights ongoing tensions in the pharmaceutical industry regarding patent enforcement and competition from generic drugs [2] - Pomerantz LLP, a prominent firm in corporate and securities litigation, is leading the investigation into Corcept's practices [1][4]